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ABSTRACT
CD99 is a cell surface molecule that has emerged as a novel target for Ewing 
sarcoma (EWS), an aggressive pediatric bone cancer. This report provides the first 
evidence of methuosis in EWS, a non-apoptotic form of cell death induced by an 
antibody directed against the CD99 molecule. Upon mAb triggering, CD99 induces 
an IGF-1R/RAS/Rac1 complex, which is internalized into RAB5-positive endocytic 
vacuoles. This complex is then dissociated, with the IGF-1R recycling to the cell 
membrane while CD99 and RAS/Rac1 are sorted into immature LAMP-1-positive 
vacuoles, whose excessive accumulation provokes methuosis. This process, which is 
not detected in CD99-expressing normal mesenchymal cells, is inhibited by disruption 
of the IGF-1R signaling, whereas enhanced by IGF-1 stimulation. Induction of IGF-
1R/RAS/Rac1 was also observed in the EWS xenografts that respond to anti-CD99 
mAb, further supporting the role of the IGF/RAS/Rac1 axis in the hyperstimulation of 
macropinocytosis and selective death of EWS cells. Thus, we describe a vulnerability 
of EWS cells, including those resistant to standard chemotherapy, to a treatment with 
anti-CD99 mAb, which requires IGF-1R/RAS signaling but bypasses the need for their 
direct targeting. Overall, we propose CD99 targeting as new opportunity to treat EWS 
patients resistant to canonical apoptosis-inducing agents.
INTRODUCTION
Ewing sarcoma (EWS) is a malignant mesenchymal 
tumor of children and young adults, with unmet clinical 
solution and relevant social impact. Despite the use of 
intensive multidrug treatments combined with surgery 
and/or radiotherapy, this highly invasive bone tumor 
forms lung and/or bone metastases in about 30-40% of 
patients with localized tumor, while approximately 30% of 
patients have detectable metastasis at diagnosis. Metastatic 
patients have very poor prognosis and treatment remains 
a challenge. The characterization of EWS genomes has 
poorly contributed to the identification of novel therapeutic 
strategies. EWS shows very low rate of somatic mutations 
[1, 2] confirming the dependence of this tumor on the 
oncogenic chimeric EWS–FLI1 protein [3]. However, 
as a transcription factor, EWS–FLI1 is a puzzling drug 
target [4], and current therapy of EWS still depends on 
conventional cytotoxic drugs with no alternative options 
for patients relapsing after first line therapies. This is 
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relevant being EWS generally resistant to apoptotic cell 
death. Mechanisms of resistance rely on either alterations 
of the glutathione pathway [5], or the constitutive 
activation of the IGF-1R, TRKB, ErbB4 [6], caveolin-1 
or PKCα [7], which may determine patients prognosis. 
The identification of novel mechanisms inducing cell 
death independently of canonical apoptosis is therefore 
imperative for developing new therapeutic approaches for 
EWS patients.
A potential method to kill cancer cells in a caspase-
independent mechanism is the hyperstimulation of 
macropinocytosis, which can induce a form of non-
apoptotic cell death, known as methuosis, death by 
macropinocytosis or catastrophic vacuolation [8-11]. 
This process is characterized by extreme accumulation 
of vacuoles in the cytoplasm, which compromises cell 
viability [12]. Methuosis was originally described after 
ectopic expression of the oncoprotein H-RAS in human 
glioblastoma, gastric carcinoma and osteosarcoma cells 
[13]. More recently, the demonstration that methuosis 
can be induced by different triggers (miRNAs, small 
molecules) in other tumors, such as papillary thyroid 
carcinoma [14], neuroblastoma [10], prostate cancer, 
breast, renal and lung cancer cells [15], has raised 
the possibility that agents capable of disrupting the 
physiological macropinosome trafficking pathways might 
be exploited for inducing cancer cell death.
CD99, a cell surface molecule [16] involved 
in several biological processes including migration, 
cell death and differentiation [17-19], is consistently 
highly expressed in EWS cells and is crucial for EWS 
malignancy. In this paper, we demonstrate that CD99 
engagement by the 0662 anti-CD99 monoclonal antibody 
(mAb) [20, 21] induces cell death of EWS cells through 
a non-apoptotic pathway resembling methuosis, which 
requires the activation of insulin-like growth factor 
receptor 1 (IGF-1R) [22, 23] and RAS-Rac1 downstream 
signaling. These data define a novel role for CD99 and 
the IGF-1R/RAS pathway in methuosis and identify 
a novel targeting approach for EWS cells, including 
chemoresistant variants.
RESULTS
CD99 triggering by 0662mAb induces massive 
macropinocytosis that results in cell death
CD99 promotes cancer cell death when triggered 
by specific antibodies, such as 0662, O13 murine mAbs 
or the human single chain fragment variable diabody 
(dAbd C7) [20]. Engagement of CD99 with antibodies 
induced fast (within 15 min) and massive annexin V 
exposition to the outside layer of cell membrane, MDM2 
ubiquitination and degradation, reactivation of p53 
signaling and mitochondrial depolarization [20, 21]. 
All EWS cells express CD99 [24] and we found that 13 
patient-derived EWS cell lines, including chemotherapy-
resistant variants, are all sensitive to CD99-induced cell 
death (Supplementary Table S1). Sensitivity of EWS cells 
to anti-CD99 antibodies correlated with the status of p53 
(p=0.048, Fisher’s exact test).
However, loss of cell viability associated with 
CD99 engagement is not prevented by the caspase 
inhibitor z-VAD-fmk and dying cells lack features 
typical of canonical apoptosis (cell shrinkage, chromatin 
condensation, DNA fragmentation) [21]. Electron 
microscopy analysis showed that anti-CD99 mAb (3μg/
ml, 30 min) induced massive vacuolization of EWS cells 
(Figure 1). The vacuoles observed in LAP-35 (Figure 1A) 
and 6647 (not shown) EWS cell lines were of various 
size (diameter range: 0.3-2.5μm), and characterized by a 
single membrane (Figure 1A: arrows), features consistent 
with macropinosomes [11]. Mitochondria and the double 
membrane typical of autophagosomes were rarely 
observed, suggesting that CD99-associated cell death 
might be related to methuosis [12], which is characterized 
by progressive accumulation of cytoplasmic vacuoles 
originating from macro- and/or micro-pinosomes [25]. 
Accordingly, necrostatin-1, an allosteric inhibitor of the 
death domain receptor-associated adaptor kinase RIP1 
which is involved in necroptosis, did not protect LAP-
35 cells from CD99-induced cell death (Supplementary 
Figure S1A). Similarly, treatments with either the 
autophagy inhibitor 3-methyladenine (3-MA), that 
prevents autophagosome formation, or knock-down 
of ATG7, a member of autophagic machinery, did not 
reduce CD99-mediated cytotoxicity (Supplementary 
Figure S1B and S1C), despite the accumulation of LC3-
IIB in LAP-35 EWS cells (Supplementary Figure S1D) 
and a punctuate pattern of LC3 distribution as detected 
by immunofluorescence analysis (Supplementary Figure 
S1E). These results indicate that autophagy, even if 
induced, is likely a compensatory stress response to 
anti-CD99 antibody treatment rather than a cell death 
mechanism.
Methuosis relies on the initial formation of vacuoles 
through clathrin-independent endocytosis and the 
progressive accumulation and enlargement of vacuoles 
up to the point of cytoplasmic membrane disruption [12]. 
Gene expression profile of 6647 EWS cells treated with 
anti-CD99 0662mAb suggests disruptions in endocytic 
processes (Supplementary Table S2). Enrichment analysis 
using Kyoto Encyclopedia of Genes and Genomes 
(KEGG) annotations revealed that the majority of 
positively modulated genes were related to endocytosis/
lysosomal pathways, particularly after 60 and 120 min 
of treatments (Supplementary Table S2). Induction 
of endocytic-like processes by anti-CD99 mAb was 
confirmed by a rapid (30 min) incorporation of tracer 
lucifer yellow (LY), a hallmark of macropinosomes, in 
6647 and LAP-35 cells after engagement of CD99 by 
0662mAb (Figure 1B and 1C), while internalization of LY 
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Figure 1: CD99 engagement by 0662 monoclonal antibody induces macropinocytosis in EWS cells. A. Transmission 
electron microscopy of untreated (CTR) or 0662mAb-treated LAP-35 cells (scale bar 2μm). The right panel is a magnification of mAb-
treated sample (scale bar 0.5μm). Arrows indicate empty vacuoles, void of cytoplasm and organelles. B. Lucifer yellow (LY) accumulation 
in 6647 or LAP-35 EWS cells in presence or not of Cytochalasin D (Cyto D) after 30 min 0662mAb exposure. Images were acquired with a 
Nikon ECLIPSE 90i with Plan Apo 60x/NA 1.4 DIC N2 (scale bar 20μm). C. Percentage of LY-positive 6647 and LAP-35 cells in presence 
or absence of 0662mAb (30 min) and/or Cyto D (60 min pretreatment). Results are represented as mean ± SEM of three independent 
experiments (*p<0.05, Student’s t test).
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was very modest in untreated cells. The phenotype was 
prevented by the macropinocytosis inhibitor cytochalasin 
D (Figure 1B and 1C).
As EWS cells are not the best model to study 
endocytosis, having large nuclei, small cytoplasm and 
growing in suspension, we alternatively used U-2 OS 
osteosarcoma cells transfected with CD99 [26]. Treatment 
of EWS or osteosarcoma U2/CD99wt57 cells with 
0662mAb triggered CD99 internalization, as shown by a 
significant decrease of CD99 cell surface levels measured 
by both flow cytometry (Figure 2A) and ELISA assay 
(Figure 2B).
CD99 significantly colocalized with caveolin-1, 
a major component of caveolae, while very limited 
colocalization was observed between CD99 and clathrin 
in both LAP-35 and U2/CD99wt57 cells (Figure 2C; 
Supplementary Figure S2A). Inhibition of clathrin-
dependent pathways with chlorpromazine did not prevent 
LY uptake after treatment with anti-CD99 0662mAb 
(Figure 2D), indicating that CD99-induced vacuoles 
derive from macropinocytosis occurring preferentially 
through a caveolin-1-enriched, but clathrin-independent 
pathway.
CD99-induced macropinocytic vacuoles contain 
the small GTPase RAB5, a marker of early endosomes, 
as well as the late endosomal/lysosomal marker LAMP-1 
(Supplementary Figure S2B). In fact, CD99 colocalized 
with both RAB5 and LAMP-1. Colocalization between 
CD99 and RAB5 was observed after 30-60 min, while 
colocalization with LAMP-1 was observed after 3h of 
antibody treatment and sustained up to 6h (Supplementary 
Figure S2B). Thus, CD99 triggering activates an endocytic 
pathway, which induces CD99 sorting into lysosomes-
like structures. However, as described for methousis 
[12], CD99-induced vacuoles are not sufficiently acidic 
to sequester lysosomotropic dyes (not shown) or to allow 
acridine orange emission to change to orange/yellow 
(Supplementary Figure S2C), thus indicating that they are 
not fully functional lysosomes. Instead, these structures 
progressively accumulate in the cytoplasm, thereby 
compromising cell viability.
CD99-induced methuosis requires activation of 
IGF-1R and RAS-Rac1 signaling
We previously reported a marked and rapid decrease 
of MDM2 protein levels following CD99 engagement 
[20]. MDM2 is an E3 ubiquitin ligase that antagonizes 
the tumor suppressor p53 [27]. In addition, MDM2 serves 
as an ubiquitin ligase for the IGF-1R, thereby promoting 
receptor degradation [28]. Thus, CD99 engagement, by 
altering MDM2 stability, may affect IGF-1R action and 
signaling. Accordingly, we detected induction of the IGF-
1R and its downstream effector RAS following CD99 
engagement (Figure 3A). Increased levels of IGF-1R are 
likely due to reduced degradation mediated by MDM2. 
In fact, engagement of CD99 did not alter transcription 
of the IGF-1R (Supplementary Figure S3A). In contrast, 
EWS cells stably or transiently overexpressing MDM2 
showed reduced levels of IGF-1R in basal condition 
and upon CD99 engagement (Supplementary Figure 
S3B and S3C), confirming that the modulation of IGF-
1R levels occurs through stabilization of the protein. In 
addition, the IGF-1R and RAS proteins colocalized as 
demonstrated by confocal microscopy (Figure 3B) and 
coimmunoprecipitated with CD99 in LAP-35 cells (Figure 
3C). Similar results were recapitulated in U2/CD99wt57 
cells (Figure 3D and 3E).
Activated forms of RAS and the IGF-1R play an 
important role in regulating caspase-independent cell 
death, associated with cytoplasmic vacuolization [11, 13, 
29]. In our cellular models, RAS and the IGF-1R were 
both internalized and sorted into early endosomes, as 
indicated by colocalization with RAB5 (Figure 4A and 
4C), but while RAS followed CD99 and colocalized 
with LAMP-1 in late endosomes/lysosome-like vacuoles 
(Figure 4B), the IGF-1R did not (Figure 4D; Mander’s 
overlap < 0.6) and colocalized instead with RAB11 
(Figure 4E), a marker of the recycling compartment [30].
Accordingly, triggering of CD99 by 0662mAb 
in presence of cycloheximide, an inhibitor of protein 
synthesis, induced partial degradation of CD99 and 
RAS but not IGF-1R down-regulation (data not shown). 
Thus, in contrast to CD99 and RAS, which are partially 
down-regulated upon antibody treatment, the IGF-1R 
is likely recycled to the cell surface in RAB11-enriched 
compartments.
In TC-71 cells silenced for IGF-1R expression 
(Supplementary Figure S4A), treatment with anti-
CD99 0662mAb failed to induce cell death, (Figure 
5A, Supplementary Figure S4B), RAS up-regulation 
(Figure 5A, Supplementary Figure S4C) and massive 
vacuolization significantly induced in TC-71 parental 
cells (Figure 5B, Supplementary Figure S4D). Conversely, 
inhibiting IGF-1R action in TC-71 EWS cells by either 
anti-IGF-1R neutralizing human antibody (hAb) AVE1642 
[31] or the tyrosine-kinase inhibitor NVP-AEW541 [32] 
reduced CD99-induced cell death, RAS up-regulation and 
inhibited massive vacuolization (Figure 5C), indicating 
that CD99-mediated cell death requires a functional 
IGF-1R. The effect of the tyrosine kinase inhibitor NVP-
AEW541 was stronger than that one observed after 
AVE1642 treatment, further suggesting that the IGF-1R 
activation likely contributes to anti-CD99 mAb activity. 
Accordingly, IGF-1 stimulation (50ng/ml, 15 min) of TC-
71 EWS cells significantly (p-value=0.0226) increased 
the percentage of dead cells, promoted RAS up-regulation 
and led to massive vacuolization (Supplementary Figure 
S4E, S4F and S4G). Overall, these results indicate that 
the IGF-1R is necessary for CD99-driven RAS induction 
and cell vacuolization. In glioblastoma RAS-induced 
cytoplasmic vacuolization does not require the activation 
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Figure 2: CD99 is internalized after 0662mAb exposure. A. Intensity of CD99 surface expression before (-) and after (+) 0662mAb 
treatment (60 min) by flow cytometry. Results are represented as mean ± SEM of three independent experiments (*p<0.05, Student’s t 
test). B. CD99 surface expression in 6647 cells by ELISA assay after 0662mAb treatment. Optical density was measured at 405nm. Data 
indicate mean relative CD99 expression ± SEM, referred to control absorbance. C. Colocalization between CD99 and Caveolin-1 or CD99 
and Clathrin in LAP-35 cells before (CTR) and after 0662mAb treatments is shown by confocal microscopy. CD99 was labeled in green, 
Caveolin-1 or Clathrin in red (scale bar 20μm) (*p<0.05, Student’s t test). Colocalization analysis was calculated by Nis Elements AR4.20.01 
software (Nikon) and MCC was represented by histograms, as mean ± SEM of an average of one hundred cells from at least 10 independent 
fields. D. LY uptake in EWS cells exposed to 0662mAb for 30 min in presence or not of Chlorpromazine (10μg/ml) (scale bar 20μm). Left 
panels: representative images of LAP-35 cells. Right panels: percentage of LY-positive 6647 or LAP-35 cells in presence or absence of 
0662mAb and/or Chlorpromazine. Results are represented as mean ± SEM of three independent experiments (Student’s t test: n.s).
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Figure 3: CD99, IGF-1R and RAS interact upon 0662mAb exposure. A. Western blot analysis of IGF-1R and pan-RAS on cell 
lysates from control (-) or 0662mAb-treated (+) EWS cells at the indicated times. Equal sample loading was monitored by anti-GAPDH 
blotting. B. Confocal microscopy shows colocalization between endogenous CD99 and IGF-1R (left panel) or CD99 and RAS (right 
panel) in LAP-35 before (CTR) and after treatment with 0662mAb. Representative images are shown. CD99 was labeled in green, IGF-
1R or RAS in red (scale bar 20μm). Values are expressed as mean ± SEM (***p<0.001, Student’s t test). C. Coimmunoprecipitation of 
endogenous IGF-1R, RAS and CD99 in LAP-35 before and after treatment with 0662mAb. D. Confocal microscopy shows colocalization 
between endogenous CD99 and IGF-1R (left panel) or CD99 and RAS (right panel) in U2/CD99wt57 cells before and after treatment with 
0662mAb. CD99 was labeled in green, IGF-1R or RAS in red (scale bar 20μm) (***p<0.001, Student’s t test). E. Western blot analysis of 
IGF-1R and pan-RAS on cell lysates from control (-) or 0662mAb-treated (+) U2/CD99wt57 cells. Loading was monitored by anti-GAPDH 
blotting. Colocalization analysis was calculated by Nis Elements AR4.20.01 software (Nikon) and MCC was represented by histograms as 
mean values ± SEM (***p<0.001, Student’s t test).
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of MAPK or PI3K pathways [33]. Accordingly, the MEK 
inhibitor PD98059 or the Akt inhibitor LY294002, as well 
as wortmannin, did not block the induction of cell death in 
our EWS cellular models [21]. In addition, the suppression 
of ERK phosphorylation in 6647 and LAP-35 EWS cells 
by stable expression of h-RAS N17 (Supplementary Figure 
S5A), a dominant negative form of RAS that inhibits 
MAPK/ERK but not Rac1/JNK responses [34], did not 
affect but rather increased vacuolization (Supplementary 
Figure S5B) and cell death (Supplementary Figure S5C) 
upon CD99 triggering.
On the contrary, no induction of vacuolization 
(Figure 6A) and a significant reversion of CD99-
induced cell death was observed in EWS cells when we 
Figure 4: RAS and IGF-1R are sorted into early endosomes but the latter is recycled to the cell surface. Confocal 
microscopy in U2/CD99wt57 before (CTR) and after 0662mAb treatment shows colocalization for: A. RAS (green) and RAB5 (red); 
B. RAS (green) and LAMP-1 (red); C. IGF-1R (green) and RAB5 (red); D. IGF-1R (green) and LAMP-1 (red); E. IGF-1R (red) and 
RAB11 (green) (scale bar 20μm). Representative images are displayed. Colocalization analysis was calculated by Nis Elements AR4.20.01 
software (Nikon) and MCC was represented by histograms as mean values ± SEM. (***p<0.001, Student’s t test).
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Figure 5: IGF-1R expression and activity are required for CD99-mediated methuosis. A. CD99-induced cell death in 
parental or IGF-1R silenced TC-71 cells (Annexin V/PI) (upper panel). Results are represented as mean ± SEM of three independent 
experiments (*p<0.05, Student’s t test). Western blotting evaluation of pan-RAS levels before (-) and after (+) treatment with 0662mAb in 
corresponding cells (lower panel). B. Vacuolization was assessed by Acridine Orange staining (AO) after 0662mAb treatment in parental 
(TC-71) or IGF-1R silenced cells (TC-siIGF1R#59) (scale bar 20μm). C. Experiments were performed in TC-71 cells before (-) and after 
(+) 15 min treatment with 0662mAb alone or in presence of either hAb AVE1642 or NVP-AEW541 (Annexin V/PI). Histograms (upper left 
panel) represent mean percentage ± SEM of dead cells (*p<0.05, Student’s t test); western blotting (upper right panel) evaluates pan-RAS 
levels in the same conditions. Lower panels display AO staining before (CTR) and after 3h treatment with 0662mAb alone or in presence 
of either hAb AVE1642 or NVP-AEW541. For AO staining, cells were acquired using the microscope Nikon ECLIPSE 90i with Plan Fluor 
40x/0.75 DIC M/N2. Pictures provided in the figures are all merged images.
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used either the specific Rac1 inhibitor EHT 1864 [35] 
(Figure 6B) or when endogenous Rac1 was depleted by 
siRNA approaches (Figure 6C). These results strongly 
indicate that the CD99/IGF-1R/RAS-mediated induction 
of methuosis in EWS occurs independently of MAPK/
ERKs signaling but through Rac1 protein, a regulator 
of actin polymerization and a positive regulator of 
macropinocitosis and phagocytosis [36, 37]. Accordingly, 
Rac1 colocalized with CD99, RAB5 and LAMP-1 in 
vacuoles following the same kinetics previously observed 
for RAS (Figure 7A, 7B and 7C). Up-regulation of IGF-
1R, RAS and Rac1 was also clearly detectable in 6647 
xenografts after treatment with anti-CD99 mAb [20, 38] 
and Rac1-positive vesicles can be identified in responsive 
tumors (Figure 8A and 8B, arrows).
CD99-induced methuosis is selective for cancer 
cells highly expressing CD99
We have previously demonstrated that engagement 
of CD99 does not affect viability of human hematopoietic 
and mesenchymal stem cells, constitutively expressing 
high levels of CD99 [20, 38]. Here, we showed that 
engagement of CD99 in mesenchymal stem cells did 
not induce macropinocytosis and massive vacuolization 
(Figure 9A) and cells showed minimal increase in RAS 
expression after CD99 triggering (Figure 9B).
On the contrary, when the murine C3H10T1/2 
mesenchymal cells transfected with both EWS-FLI1 and 
CD99 were treated with the 0662mAb, they underwent 
catastrophic vacuolization, restored RAS induction (Figure 
9C) and died [20]. Conversely, EWS cells resistant to the 
anti-CD99 0662mAb because of decreased CD99 levels 
on cell surface (6647/CD99low) did not induce RAS up-
regulation and cytoplasmic vacuolization, when exposed 
to the antibody (Figure 9D). These data indicate that 
aberrant high expression of CD99 is absolutely required 
to activate catastrophic vacuolization and death.
These results additionally support the validity and 
specificity of anti-CD99 antibodies as a therapeutic tool 
for EWS treatment.
DISCUSSION
In this paper, we provide the novel observation 
that engagement of CD99 with the 0662mAb activated 
a methuosis-like process that depends on the IGF-1R/
Figure 6: Rac1 inhibition reverts CD99-mediated effects. A. AO staining was performed in 6647 cells before (CTR) or after 
exposure with 0662mAb (3h) alone or combined with the Rac1 inhibitor EHT 1864 (25 μM). For AO staining, cells were acquired using 
the microscope Nikon ECLIPSE 90i with Plan Fluor 40x/0.75 DIC M/N2. Pictures provided are all merged images (scale bar 20μm). B. 
Percentage of 6647 live cells before (-) and after (+) treatment with anti-CD99 0662mAb alone, or with Rac1 inhibitor EHT 1864 (25 
μM for 48 h pretreatment) (trypan blue dye exclusion). C. Percentage of live 6647 cells before (-) and after (+) treatment with anti-CD99 
0662mAb and/or with siRNA against Rac1. Cells were transfected by a scrambled (SCR) as control (trypan blue dye exclusion). Results 
are expressed as mean ± SEM of three or more independent experiments (Student’s t test: *p< 0.05; **p<0.01).
A
B C
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RAS/Rac1 signaling cascade and lead to cell death 
in 13 patient-derived EWS cell lines, including those 
resistant to conventional chemotherapy. We also provided 
evidence that this mechanism is functional in 6647 EWS 
xenografts derived from mice treated with anti-CD99 
mAb, supporting the in vivo relevance of our study. 
CD99 is expressed on the cell surface and it is detectable 
in virtually all EWS cases [24]. CD99 is critical for 
the pathogenesis of this tumor and it can be targeted in 
combination with conventional treatments [20, 38]. Thus, 
CD99 targeting has great clinical potential for EWS 
therapy.
CD99 triggering by 0662mAb mimics apoptotic 
stimuli [20, 21] but does not induce classical caspase-
dependent apoptosis and triggers caveolin-regulated but 
clathrin-independent endocytosis, which accumulates 
defective vacuoles in the cytoplasm, thereby compromising 
viability. This process, known as methousis or death 
by macropinocytosis, has been previously described 
as an efficient mean of inducing cell death in different 
types of cancers [8-12]. In contrast to physiological 
macropinocytosis, methuosis is characterized by 
dysregulated clearance of vacuoles associated with 
insufficient recycling or fusion with other endosomal 
compartments. The nascent vacuoles acquire late 
endosomal/lysosomal markers such as LAMP-1 but do not 
contain lysosomal enzymes and acidic pH, as is the case 
of functional lysosomes [39]. Loss of viability may derive 
from cytoplasmic hyper-vacuolization associated with loss 
of metabolic capacity (decrease in ATP and mitochondrial 
Figure 7: Rac1 colocalizes with CD99 and is sorted into vacuoles after 0662mAb treatment. In U2/CD99wt57 before (CTR) 
and after 0662mAb treatment confocal microscopy shows colocalizations for A. CD99 (green) and Rac1 (red); B. Rac1 (green) and RAB5 
(red); C. Rac1 (green) and LAMP-1 (red) (scale bar 20μm). Representative images are displayed. Colocalization index (MCC) represented 
by histograms was calculated by Nis Elements AR4.20.01 software (Nikon) and expressed as mean values ± SEM (***p<0.001, Student’s 
t test).
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potential) and plasma membrane integrity, without cell 
shrinkage and nuclear fragmentation associated with 
canonical apoptosis.
The signaling pathways that sustain methuosis are 
in part cell system-dependent but few common features 
have been so far defined. The process requires clathrin-
independent endocytosis and mechanisms that converge 
on the regulation of actin dynamics and RAS signaling.
Maltese and colleagues firstly provided the evidence 
that induction of methuosis might only occur when the 
level of active RAS reaches a threshold sufficient to 
stimulate Rac1, thereby leading to inactivation of Arf6, 
a small GTPase that promotes recycling from clathrin-
independent endosomes to plasma membranes [13]. Thus, 
Rac1-regulated vacuoles cannot recycle to the surface or 
fuse to lysosomes; instead, they fuse to each other and 
Figure 8: IGF-1R/RAS/Rac1 signaling is activated upon anti-CD99 treatment in vivo. A. Mean tumor volumes in control and 
in CD99-antibody treated mice (Values are mean ± SEM, *p<0.05, Student’s t test). B. Representative immunohistochemical evaluation 
of IGF-1R, RAS and Rac1 expression in untreated or anti-CD99 treated mice. Hematoxilin and Eosin staining was used to evaluate cell 
morphology. Enlarged views of the boxed regions are shown below. Arrows indicate Rac1 positive vesicles (scale bar 50μm).
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late endosomes creating large vacuoles that accumulate 
in the cytoplasm. The induction of methuosis caused by 
overexpression of RAS (G12V) is a slow process and may 
take several days. On the contrary, the anti-CD99 mAb as 
well as small molecules that drive methuosis [8, 40] can 
induce vacuolization within 1-4 hours, supporting their 
possible application in the clinic. Intriguingly, the cell-
death promoting role of RAS has been characterized in the 
context of wild-type RAS up-regulation, whereas in cells 
carrying RAS mutations macropinocytosis was described 
as a mechanism supplying cancer cells with aminoacids to 
sustain proliferation [41]. This might indicate a profound 
difference between tumors with rare or high frequency of 
RAS mutations, highlighting the importance of the cellular 
context in defining therapeutic approaches. Significantly, 
EWS belongs to the class of tumors with low rate of RAS 
Figure 9: RAS and CD99 levels are crucial for 0662mAb-induced vacuolization. A. AO staining of human mesenchymal stem 
cells (hMSCs) treated or not (CTR) with the anti-CD99 0662mAb. Representative merged images are shown (scale bar 20μm). B. Western 
blotting evaluation of pan-RAS levels before (-) and after treatment with anti-CD99 0662mAb in 6647 cells or hMSC cells. GAPDH was 
used as loading control. C. Left: AO staining of murine MSCs transfected with EWS/FLI1 and CD99 (C3H10T1/2 EF CD99) treated or 
not (CTR) with the anti-CD99 0662mAb. Representative merged images are shown (scale bar 20μm). Right: western blotting evaluation 
of pan-RAS levels before (-) and after treatment with 0662mAb in C3H10T1/2 EF CD99. GAPDH was used as loading control. D. Left: 
AO staining of 6647/CD99low cells treated or not (CTR) with the anti-CD99 0662mAb. Representative merged images are shown (scale bar 
20μm). Middle: western blotting evaluation of pan-RAS levels before (-) and after (+) treatment with 0662mAb for 1h in 6647/CD99low. 
GAPDH was used as loading control. Right: percentage of live cells before (-) and after (+) treatment with anti-0662mAb in 6647/CD99low 
(Annexin V/PI assay). Values represent mean ± SEM of three independent experiments (Student’s t test: p> 0.05).
Oncotarget79937www.impactjournals.com/oncotarget
mutations [2, 42] suggesting that this particular tumor 
context may favor RAS signaling and methuosis.
Here, we elucidated the molecular events that, upon 
CD99 engagement, led to cell death and demonstrated 
that CD99, when engaged by 0662mAb, rapidly 
evokes caveolin-1-dependent endocytosis and fosters 
up-regulation of IGF-1R and RAS/Rac1 induction. 
Increased IGF-1R levels likely occurs through CD99-
induced degradation of MDM2 [20], which impairs IGF-
1R ubiquitination and degradation, as in fact MDM2, 
in addition to control of p53 levels, also serves as an 
ubiquitin ligase for the IGF-1R [43]. CD99 colocalizes 
with caveolin-1 [26], the IGF-1R, RAS and Rac1 in 
endosomes that are initially characterized by RAB5 
expression and are later enriched in LAMP-1. However, 
while CD99, RAS and Rac1 are then sorted into late-
endosomes that may partially retain the ability to merge 
with lysosomes, thereby inducing partial degradation of 
the molecules, the IGF-1R is rapidly sorted back to the 
cell surface through RAB11-dependent recycling. Thus, 
IGF-1R recycling may constitute an additional mechanism 
contributing to enhanced IGF-1R levels.
Stimulation of the IGF-1R was functionally 
necessary for CD99-induced RAS up-regulation and 
cell vacuolization. Considering that EWS cells display 
autocrine activation of IGF-1R, its recycling to cell 
membrane and consequent phosphorylation may work to 
ensure the maintenance of sustained levels of RAS and 
Rac1 signaling.
Inhibiting Rac1 interaction with its downstream 
effectors by either specific inhibitors [35] or siRNA 
approaches significantly inhibited CD99-induced 
vacuolization and cell death, indicating that Rac1 induced 
expression downstream of the IGF-1R/RAS complex is a 
critical determinant of CD99-induced cell death. At least 
two additional groups have identified small molecules 
that specifically induce methuosis by mechanisms 
dependent on Rac1 activity [8, 40]. Our work extends 
these observations showing the up-regulation of IGF-1R/
RAS/Rac1 signaling after CD99 triggering in vivo and the 
formation of Rac1-positive vesicles in responsive tumors.
The discovery that anti-CD99 0662mAb exerts 
its anti-tumor action by enhancing IGF-1R/RAS/Rac1 
activity may seem paradoxical. In fact, besides the 
well-known role of IGF-1R in promoting EWS cell 
malignancy [22, 44], Rac1 has been discovered as a key 
mediator of EWS cell invasion and metastasis [45, 46]. 
However, we believe that the induction of methuosis may 
explain this paradox. Rapid stimulation of physiological 
macropinocytosis upon IGF-1 exposure is one of the early 
events of IGF-1R signaling [47] and occurs to sustain 
cell proliferation and survival. The interaction between 
the IGF-1R and CD99, triggered by the 0662mAb, 
may modify actin dynamics and shift physiological 
macropinocytosis towards methuosis. Neither RAS nor 
Rac1 are mutated in EWS [2, 42], where aberrant activity 
is the result of altered expression and localization [11, 
48]. Thus, CD99 may affect Rac1 downstream molecular 
interactions and specificity of response by sequestering 
RAS-Rac1 into vacuoles.
The results presented in this paper may have 
important clinical implications. Our data suggest that 
combining IGF-1R inhibitors with anti-CD99 mAb may 
have an antagonistic effect. In contrast, CD99 triggering 
exploits the constitutive activation of the IGF-1R, which is 
sustained by EWS-FLI [49], and drives cells toward death.
Toxicity remains a major issue in the drug 
development process and it is particular relevant for 
pediatric diseases. Here we showed that treatment with 
anti-CD99 0662mAb of normal human bone-marrow 
derived MSC cells, expressing CD99 at levels similar 
to EWS cells [20], did not induce hyperstimulation of 
vacuoles or RAS up-regulation. Accordingly, MSC cells 
are not susceptible to cell death, confirming previous 
results in other cellular models [8, 11, 15, 41, 50]. When 
MSC cells ectopically expressed EWS-FLI and CD99, 
they regain the ability to respond to anti-CD99 antibody 
entering a methuosis-like process. The effects are more 
dramatic in malignant cells with higher expression of 
CD99, as shown in CD99-resistant EWS cells. In addition, 
reactivation of p53 following CD99 engagement [20] may 
synergize with the death-promoting effects of RAS [51], 
further increasing treatment efficacy. Both p53 reactivation 
[20] and RAS induction could not be triggered in normal 
MSC cells after treatment with anti-CD99.
Overall, our data prove that CD99-induced 
macropinocytosis selectively destroys EWS cells, even 
when they are chemoresistant. As of today, antibodies 
against CD99 and few other small molecules are the 
only agents that may specifically induce methuosis [8, 
40]. CD99 triggering activates an “apoptotic mimicry” 
mechanism that induces a methuosis-like process leading 
to cell death. We clearly show that CD99-antibody 
exploits a constitutively active IGF-1R to initiate RAS/
Rac1 signaling, defective vacuolization and death. 
Interestingly, the process is enhanced in the presence of 
high concentration of IGF-1, which leads to increased 
percentage of EWS cell death. This is critical considering 
that IGFs are the prevalent growth factors of bone. Their 
release by tumor cell-induced bone destruction may 
therefore activate an autocrine mechanism, which may 
improve treatment efficacy against primary and metastatic 
tumors.
MATERIALS AND METHODS
Cell lines and primary cell cultures
EWS cell lines were grown as previously described 
[20, 26]. 6647 and TC-71 were kindly provided by T.J. 
Triche (Children's Hospital, Los Angeles, CA, 1994); 
RD-ES, SK-ES-1, SK-N-MC (1994) were provided by 
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American Type Culture Collection, ATCC (Rockville, 
MD); H825 and H-1474-P2 were kindly provided by 
Prof Llombart-Bosch (2001); C3H10T1/2 EF CD99 was 
kindly provided by F. Lecanda, (2007) [52]. LAP-35 
(1987); IOR/BRZ_2010 (1995); U2/CD99wt57 (2001) 
[26]; TC-71 siIGF-1R (2006); TC/ET 12nM (2002) [53]; 
6647/CD99low (2009) [52] were previously established in 
our laboratory; DOXO variants of TC-71 was obtained 
by transfection with a vector containing MDR1 cDNA 
and selected in doxorubicin (30ng/ml, SIGMA) [53]. 
LAP-35 variants stably overexpressing MDM2 were 
previously characterized [20]. All cell lines were tested 
for mycoplasma (MycoAlert mycoplasma detection kit, 
Lonza) and authenticated by STR PCR analysis within 
last year (GenePrint® 10 System or POWERPLEX EXS 
17 fastsystem, Promega). Bone marrow-derived human 
mesenchymal (hMSC) stem cells were obtained from 
healthy donors or patients with benign bone lesions. 
hMSC cells characterized for mesenchymal markers and 
differentiative ability were used at early passages.
Stable and transient transfections and lentiviral 
infections
Transfections were performed using Calcium 
Phosphate transfection Kit or Lipofectamine 2000 (Life 
Technologies) according to the manufacturer’s protocol. 
Transient transfection of MDM2 gene was performed 
with pCMV-MDM2 [20]. Transient silencing of Rac1 
was obtained by using anti-Rac1 oligos as previously 
described [54]. For stable silencing of IGF-1R, TC-71 
cells were transfected with pSilencer™ -2.1.U6 neo 
(Ambion) containing the sequence for IGF-1R short 
hairpin RNA and selected with G418 (500 μg/ml). 6647 
and LAP-35 cells were infected with pBABEpuro-
HRASN17 or pBABEpuro empty vector supernatants, 
and DN cells were selected with puromycin (500 ng/ml). 
pLKO.1 shAtg7-E8 (TET-ON inducible) and pGIPZ sh 
SCR (constitutive) were transfected on HEK293T cells 
to generate lentiviral supernatant to infect 6647 cell line. 
Cells were selected with puromycin (500 ng/ml). For 
silencing induction cells were exposed to tetracycline 
2.5μg/ml.
Treatment with conventional drugs
Sensitivity to chemotherapeutics was assessed 
after 72h of treatment with TACS® MTT Cell 
Proliferation Assay kit (TREVIGEN, Inc.) accordingly to 
manufacturer’s instructions.
0662mAb and inhibitors treatment
The anti-CD99 0662 monoclonal antibody (mAb) 
was produced in the Unité INSERM 343, Hospital de 
l’Archet, Nice, France. Treatments with 0662mAb (3μg/
ml) were performed in adhesion or at the concentration of 
5 × 106/ml cells as previously described [20, 21]. After the 
indicated time-points, samples were tested for Annexin-V/
propidium iodide (Mebcyto apoptosis Kit, MBL), protein 
extraction or specific assays. The following inhibitors 
were used alone or in combination with 0662mAb: 
necrostatin-1 (50μM), 3-methyladenine (3-MA) (5mM, 
Sigma), Cytochalasin D (5μg/ml, Sigma) pre-treatment 
at 37°C for 60 min, chlorpromazine (10μg/ml, Sigma) 
pretreatment at 37°C for 30 min, anti-IGF-1R neutralizing 
antibody AVE1642 [55] (100ng/ml, kindly provided by 
ImmunoGen Inc), tyrosine kinase inhibitor NVP-AEW541 
(1μM, kindly provided by Novartis) pre-treatment at 37°C 
for 60 min. The Rac1 inhibitor, EHT 1864 (Tocris), was 
added at 25μM in culture medium 24h after cell seeding 
and renewed every day. After 48h of treatment, cells were 
trypsinized, treated with 3μg/ml of 0662mAb for 4h and 
harvested for vital count. 24h 1% FBS-starved cells were 
treated with IGF-I (50ng/ml) alone or in combination with 
0662mAb.
Electron microscopy analysis
6647 and LAP-35 untreated or treated cells were 
fixed with 2.5% glutaraldehyde in 0.1M cacodylate 
buffer, pH 7.4, post-fixed with 1% OsO4, dehydrated to 
absolute ethanol and embedded in Epon. Ultrathin sections 
were stained with uranyl acetate and lead citrate before 
observation with a Zeiss EM109 electron microscope. 
Images were captured using a Nikon digital camera 
Dmx1200F and ACT-1 software.
Flow cytometry and immunostaining
Standard protocols were followed as described 
in Supplementary Materials and Methods). For 
colocalization investigations by immunofluorescence 
images were acquired and analyzed with a Nikon A1R 
confocal microscope with a Plan Apo 60x/NA 1.4 DIC 
N2. Pictures are representative of at least 10 independent 
fields from three independent experiments. Fields were 
selected for the presence of cells with the following 
criteria: well defined limits, clear identification of 
nucleus and absence of intersection with neighboring 
cells. Colocalization analysis was performed both with 
Pearson Colocalization Coefficient (PCC) and Mander’s 
Colocalization Coefficient (MCC, shown in the paper) 
and calculated by Nis Elements AR4.20.01 software 
(Nikon). Colocalization index was represented by 
histograms as mean ± SEM.
Western blotting and immunoprecipitation
Details about western blotting and 
immunoprecipitation are provided in Supplementary 
Materials and Methods.
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CD99 internalization by ELISA and flow 
cytometry analysis
ELISA assays were performed in 6647 cell line as 
previously described [56] The expression of CD99 was 
analyzed by flow cytometry analysis (FACS-Calibur, 
Becton Dickinson), see Supplementary Materials and 
Methods.
Gene expression profile and network analyses
Cell lines were profiled by Agilent-012097 Human 
1A Microarray (V2) G4110B 20K arrays. Microarray 
data are available at GEO database with Series accession 
number GSE36097 [21]. Enrichment analysis was 
performed by MetaCore in GeneGO (Thomson Reuters, 
New York, NY, USA) and by DAVID [57] programs. For 
details refer to Supplementary Materials and Methods.
Lucifer yellow incorporation assay
In order to visualize macropinosomes upon 
treatments, cells were incubated with 0.75 mg/ml Lucifer 
Yellow (LY) fluid-phase dye (Thermo Scientific) in IMDM 
10% FBS for 15 min at 37°C. Tracer incorporation was 
evaluated by flow cytometry analysis (FACS-Calibur, 
Becton Dickinson) or by visual imaging (Nikon ECLIPSE 
90i with Plan Apo 60x/NA 1.4 DIC N2). Images were 
captured under identical conditions using a digital color 
camera (Nikon DS5MC) and the software NIS-Elements 
AR 3.10 (Nikon).
Acridine orange immunofluorescence
To track acidic vescicles formation, Acridine 
Orange (AO, Sigma) staining was performed as described 
in Supplementary Materials and Methods. Cells were 
acquired with Nikon ECLIPSE 90i with Plan Fluor 
40x/0.75 DIC M/N2 using either a blue light excitation 
(492 nm) with a 540-550 nm emission filter (lysosomes 
appear yellowish green), or green light excitation (540 nm) 
with a long pass >640 nm barrier filter (lysosomes appear 
red). Images were captured under identical conditions 
using a digital color camera (Nikon DS5MC) and merged 
by the software NIS-Elements AR 3.10 (Nikon).
Statistical analysis
Differences among means were analyzed by 
Student’s t test. Fisher’s exact test was used to evaluate 
the statistical association between two variables.
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